Ghent University Academic Bibliography

Advanced

Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib?: reply

Isabelle Colle UGent and Christophe Van Steenkiste UGent (2011) HEPATOLOGY. 54(5). p.1891-1891
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (letterNote)
publication status
published
subject
journal title
HEPATOLOGY
Hepatology
volume
54
issue
5
pages
1891 - 1891
Web of Science type
Letter
Web of Science id
000296443100042
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
11.665 (2011)
JCR rank
2/73 (2011)
JCR quartile
1 (2011)
ISSN
0270-9139
DOI
10.1002/hep.24729
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1997724
handle
http://hdl.handle.net/1854/LU-1997724
date created
2012-01-20 09:29:33
date last changed
2016-12-19 15:42:54
@article{1997724,
  author       = {Colle, Isabelle and Van Steenkiste, Christophe},
  issn         = {0270-9139},
  journal      = {HEPATOLOGY},
  language     = {eng},
  number       = {5},
  pages        = {1891--1891},
  title        = {Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib?: reply},
  url          = {http://dx.doi.org/10.1002/hep.24729},
  volume       = {54},
  year         = {2011},
}

Chicago
Colle, Isabelle, and Christophe Van Steenkiste. 2011. “Targeting Angiogenesis in Chronic Liver Diseases with Portal Hypertension: Anti-placenta Growth Factor Inhibitor or Multikinase Inhibitor Sorafenib?: Reply.” Hepatology 54 (5): 1891–1891.
APA
Colle, I., & Van Steenkiste, C. (2011). Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib?: reply. HEPATOLOGY, 54(5), 1891–1891.
Vancouver
1.
Colle I, Van Steenkiste C. Targeting angiogenesis in chronic liver diseases with portal hypertension: anti-placenta growth factor inhibitor or multikinase inhibitor sorafenib?: reply. HEPATOLOGY. 2011;54(5):1891–1891.
MLA
Colle, Isabelle, and Christophe Van Steenkiste. “Targeting Angiogenesis in Chronic Liver Diseases with Portal Hypertension: Anti-placenta Growth Factor Inhibitor or Multikinase Inhibitor Sorafenib?: Reply.” HEPATOLOGY 54.5 (2011): 1891–1891. Print.